Abstract
Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterised by multiple motor and vocal tics, plus associated behavioural symptoms. Tics are defined as sudden, rapid, repetitive non-rhythmic movements (motor tics) or vocalisations (vocal tics). Tics are distressing symptoms and can lead to considerable disruption to social functioning and quality of life. Converging evidence from different lines of research suggests that the pathophysiology of TS involves altered dopaminergic transmission in the cortico-striatal–thalamo-cortical circuits, along with other neurotransmitter systems. Pharmacotherapy is currently the treatment of choice in patients with moderate-to-severe tics, particularly when associated with deterioration in social, occupational or academic performance. This review will focus on the recent evidence base supporting the use of different medication classes for the treatment of tics in TS. The recent publication of the European and Canadian guidelines on the management of TS are based on experts’ consensus and highlight the need for randomised controlled trials, especially with regards to newly developed pharmacological agents.
Similar content being viewed by others
References
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed., text revision. American Psychiatric Association: Washington, DC
Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM (1983) Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 11:205–208
Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry 20:155–171
Cavanna AE, Servo S, Monaco F, Robertson MM (2009) The behavioral spectrum of Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci 21:13–23
Cavanna AE, Selvini C, Termine C, Luoni C, Eddy CM, Rickards H (2012) Tolerability profile of aripiprazole in patients with Tourette syndrome. J Psychopharmacol 26:891–895
Dion Y, Annable L, Sandor P, Chouinard G (2002) Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31–39
Drtilkova I, Balastikova B, Lemanova H, Zak J (1994) Therapeutic effects of clonidine and clonazepam in children with tick syndrome. Homeostasis Health Dis 35:296
Eddy CM, Rickards HE, Cavanna AE (2011) Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord 4:25–45
Goetz CG (1992) Clonidine and clonazepam in Tourette syndrome. Adv Neurol 58:245–251
Gulisano M, Calì PV, Cavanna AE, Eddy C, Rickards H, Rizzo R (2011) Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 32:1213–1217
Hassan N, Cavanna AE (2012) The prognosis of Tourette syndrome: implications for clinical practice. Funct Neurol 27:23–27
Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J (2012) Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat 8:95–104
Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358–362
Jankovic J, Jimenez-Shahed J, Brown L (2010) A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81:70–73
Ji WD, Li Y, Li N, Guo BY (2005) Olanzapine for treatment of Tourette syndrome: a double-blind randomized controlled trial. Chinese J Clin Rehab 9:66–68
Liu ZS, Chen YH, Zhong YQ, Zou LP, Wang H, Sun D, Wang DB, Liao JX (2011) A multicentre controlled study on aripiprazole treatment for children with Tourette syndrome in China. Zhonghua Er Ke Za Zhi 49:572–576
McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, Sanberg PR (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette’s disorder. Am J Psychiatry 148:793–794
Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495
Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57–61
Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003a) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459–465
Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003b) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384–388
Muller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, Visser-Vandewalle V, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 20:209–217
Piedad JCP, Rickards HE, Cavanna AE (2012) What patients with gilles de la tourette syndrome should be treated with deep brain stimulation and what is the best target? Neurosurgery 71:173–192
Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D (2008) Tourette’s syndrome and the role of tetrabenazine: review and personal experience. Clin Drug Investig 28:443–459
Pringsheim T, Marras C (2009) Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2:CD006996
Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (2012) Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 57:133–143
Robertson MM (2011) Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med 72:100–107
Robertson MM, Schneider V, Lees AJ (1990) Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropsychopharmacol 13:229–235
Robertson MM, Eapen V, Cavanna AE (2009) The international prevalence, epidemiology and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 67:475–483
Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatr 20:173–196
Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. Am J Psychiatr 154:1057–1062
Sandor P, Musisi S, Moldofsky H, Lang A (1990) Tourette syndrome: a follow-up study. J Clin Psychopharmacol 10:197–199
Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135
Scahill L, Erenberg G, Berlin CM, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J, Tourette Syndrome Association Medical Advisory Board: Practice Committee (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3:192–206
Shapiro AK, Shapiro E, Eisenkraft GJ (1983) Treatment of Gilles de la Tourette syndrome with clonidine and neuroleptics. Arch Gen Psychiatr 40:1235–1240
Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandell J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatr 46:722–730
Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB (1995) The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind, placebo controlled study with clonidine and desipramine. Pediatrics 95:74–81
Steeves T, McKinlay BD, Gorman D, Billinghurst L, Day L, Carroll A, Dion Y, Doja A, Luscombe S, Sandor P, Pringsheim T (2012) Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation. Can J Psychiatry 57:144–151
Verdellen C, van de Griendt J, Hartmann A, Murphy T, ESSTS Guidelines Group (2012) European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry 20:197–207
Acknowledgments
The authors are grateful to Tourettes Action-UK and USA-Tourette Syndrome Association for their continuing support.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thomas, R., Cavanna, A.E. The pharmacology of Tourette syndrome. J Neural Transm 120, 689–694 (2013). https://doi.org/10.1007/s00702-013-0979-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-013-0979-z